ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum

Immunitybio Inc ( (IBRX) ) has released its Q1 earnings. Here is a breakdown of the information Immunitybio Inc presented to its investors.

ImmunityBio, Inc. is a biotechnology company focused on developing next-generation immunotherapies and vaccines to combat cancers and infectious diseases, leveraging its unique platforms to enhance immune responses.

In its latest earnings report, ImmunityBio announced a significant increase in net revenue and unit sales for the first quarter of 2025, driven by the introduction of a permanent J-code that facilitated billing and reimbursement processes. The company also highlighted its strategic efforts to address the Bacillus Calmette-Guérin (BCG) shortage and expand the market for its ANKTIV A product.

Key financial metrics revealed a 129% increase in net product revenue, reaching $16.5 million in Q1 2025 compared to the previous quarter. ANKTIV A unit sales surged by 150%, reflecting strong demand and market penetration. Additionally, ImmunityBio’s research and development expenses decreased, contributing to a reduced net loss of $129.6 million, down from $134.1 million in the same quarter of the previous year.

The company also completed a $75 million equity financing in April 2025 to support its ongoing operations and further development of its product pipeline. Positive results from the QUILT 3.032 study were announced, showcasing the potential of ANKTIV A in treating non-muscle invasive bladder cancer.

Looking ahead, ImmunityBio remains optimistic about its growth prospects, with management expressing confidence in the continued development of advanced treatment candidates and expanding market opportunities for its innovative therapies.